 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Somagenics Holds Back on HCV Clinical Trial Amid Advances by Other Drugmakers
November 29, 2012
Somagenics Holds Back on HCV Clinical Trial Amid Advances by Other Drugmakers
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Oligo Drugs Advance in the Clinic in 2012 as Delivery Hurdles are Addressed
January 3, 2013 / Gene Silencing News - Sirnaomics Nears Phase I Study of Wound-Healing Drug as It Eyes the microRNA Field
June 28, 2012 / Gene Silencing News - Tools & Techniques: Quantum Dot-based microRNA Detection; siRNA Delivery to Leukemia Cells; and More
June 20, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Asuragen, Merck, Alnylam, and More
June 20, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Rosetta, Venganza, Alnylam, and More
June 13, 2013 / Gene Silencing News